Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. 2015

A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
Gelre Hospitals, Apeldoorn, the Netherlands.

Renal function deterioration is a rather frequent side effect of ticagrelor; this is especially so in patients over the age of 75, with pre-existent mild renal failure and/or taking an angiotensin receptor inhibitor. We describe a patient in whom deterioration of renal function due to ticagrelor led to a rise in serum concentration of rosuvastatin which resulted in rhabdomyolysis. The presented case emphasises the importance to check renal function routinely before and one month after starting ticagrelor and to screen carefully for possible interactions with other drugs.

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068718 Rosuvastatin Calcium A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES. Crestor,Rosuvastatin,ZD 4522,ZD4522,Calcium, Rosuvastatin
D000077486 Ticagrelor An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION. 3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol,AZD 6140,AZD-6140,AZD6140,Brilinta,Brilique
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012206 Rhabdomyolysis Necrosis or disintegration of skeletal muscle often followed by myoglobinuria. Rhabdomyolyses
D058186 Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions. Acute Kidney Failure,Acute Kidney Insufficiency,Acute Renal Failure,Acute Renal Injury,Acute Renal Insufficiency,Kidney Failure, Acute,Kidney Insufficiency, Acute,Renal Failure, Acute,Renal Insufficiency, Acute,Acute Kidney Failures,Acute Kidney Injuries,Acute Kidney Insufficiencies,Acute Renal Failures,Acute Renal Injuries,Acute Renal Insufficiencies,Kidney Failures, Acute,Kidney Injuries, Acute,Kidney Injury, Acute,Kidney Insufficiencies, Acute,Renal Failures, Acute,Renal Injuries, Acute,Renal Injury, Acute,Renal Insufficiencies, Acute
D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. HMG-CoA Reductase Inhibitor,HMG-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitor,Statin,Statins, HMG-CoA,Inhibitors, HMG-CoA Reductase,Inhibitors, Hydroxymethylglutaryl-CoA,Inhibitors, Hydroxymethylglutaryl-Coenzyme A,Statins,HMG CoA Reductase Inhibitor,HMG CoA Reductase Inhibitors,HMG-CoA Statins,Hydroxymethylglutaryl CoA Reductase Inhibitor,Hydroxymethylglutaryl CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Inhibitors,Hydroxymethylglutaryl-Coenzyme A Inhibitors,Inhibitors, HMG CoA Reductase,Inhibitors, Hydroxymethylglutaryl CoA,Inhibitors, Hydroxymethylglutaryl Coenzyme A,Inhibitors, Hydroxymethylglutaryl-CoA Reductase,Reductase Inhibitor, Hydroxymethylglutaryl-CoA,Reductase Inhibitors, HMG-CoA,Reductase Inhibitors, Hydroxymethylglutaryl-CoA,Statins, HMG CoA

Related Publications

A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
November 2017, The American journal of case reports,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
August 2017, Cureus,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
May 2004, Anales de medicina interna (Madrid, Spain : 1984),
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
March 1997, Renal failure,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
March 2017, Journal of clinical and diagnostic research : JCDR,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
May 2019, The American journal of case reports,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
April 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
May 2016, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
July 2016, The Journal of the Association of Physicians of India,
A J van Vuren, and B de Jong, and H P R Bootsma, and M J Van der Veen, and G W Feith
January 2020, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!